Trademark: 97671247
Word
ADVANZ
Status
Pending
Status Code
686
Status Date
Tuesday, May 14, 2024
Serial Number
97671247
Mark Type
4
Filing Date
Thursday, November 10, 2022
Published for Opposition
Tuesday, May 14, 2024

Trademark Owner History
Mercury Pharma Group Limited - Owner At Publication

Classifications
5 A full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus and instruments, and surgical implants comprised of human and animal tissue; all of the foregoing excluding anti-infective pharmaceutical preparations
10 Medical devices, namely, lasers and fibre-optic wires and cables for use in photodynamic therapy with the administration of a photosensitizing agent for the treatment of cancer

Trademark Events
Nov 14, 2022
New Application Entered
Nov 30, 2022
New Application Office Supplied Data Entered
Jan 18, 2023
Assigned To Examiner
Jan 19, 2023
Examiners Amendment -Written
Jan 19, 2023
Examiners Amendment E-Mailed
Jan 19, 2023
Notification Of Examiners Amendment E-Mailed
Jan 19, 2023
Examiner's Amendment Entered
Feb 16, 2023
Priority Action Written
Feb 16, 2023
Priority Action E-Mailed
Feb 16, 2023
Notification Of Priority Action E-Mailed
May 16, 2023
Application Extension To Response Period - Received
May 16, 2023
Application Extension Granted/Receipt Provided
Aug 16, 2023
Teas Response To Office Action Received
Aug 16, 2023
Correspondence Received In Law Office
Aug 17, 2023
Teas/Email Correspondence Entered
Sep 27, 2023
Final Refusal Written
Sep 27, 2023
Final Refusal E-Mailed
Sep 27, 2023
Notification Of Final Refusal Emailed
Oct 24, 2023
Exparte Appeal Received At Ttab
Oct 24, 2023
Jurisdiction Restored To Examining Attorney
Oct 24, 2023
Ex Parte Appeal-Instituted
Oct 24, 2023
Teas Request For Reconsideration Received
Mar 12, 2024
Assigned To Lie
Mar 12, 2024
Correspondence Received In Law Office
Mar 12, 2024
Teas/Email Correspondence Entered
Apr 9, 2024
Approved For Pub - Principal Register
Apr 9, 2024
Exparte Appeal Terminated
Apr 24, 2024
Notification Of Notice Of Publication E-Mailed
May 14, 2024
Published For Opposition
May 14, 2024
Official Gazette Publication Confirmation E-Mailed

Trademark Alertz updated from USPTO on 2030-01-24